0001193125-21-339389.txt : 20211124 0001193125-21-339389.hdr.sgml : 20211124 20211124075058 ACCESSION NUMBER: 0001193125-21-339389 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20211122 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20211124 DATE AS OF CHANGE: 20211124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 211441268 BUSINESS ADDRESS: STREET 1: 5 BAZEL ST STREET 2: P O B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 BUSINESS PHONE: 9729267267 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 5 BAZEL ST PO B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 8-K 1 d222550d8k.htm 8-K 8-K
TEVA PHARMACEUTICAL INDUSTRIES LTD IL 00-0000000 false 0000818686 0000818686 2021-11-22 2021-11-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 22, 2021

 

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Exact name of registrant as specified in its charter)

 

 

 

Israel   001-16174   Not Applicable

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

  (IRS Employer
Identification Number)

124 Dvora Hanevi’a Street

Tel Aviv 6944020, Israel

(Address of Principal Executive Offices, including Zip Code)

+972-3-914-8213

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Copies of communications to:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

American Depositary Shares, each representing one Ordinary Share   TEVA   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


ITEM 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b)    Departure of Andrew Weil, Chief Accounting Officer

Andrew Weil, Teva’s Chief Accounting Officer, will step down from his role as Chief Accounting Officer, effective November 24, 2021.

(c)    Appointment of Amir Weiss as Chief Accounting Officer

Amir Weiss, currently Vice President of Finance and Corporate Controller, was promoted to Senior Vice President and Chief Accounting Officer, effective November 24, 2021.

Mr. Weiss, 44, joined Teva in June 2012 and has served in several senior finance-related positions, including Vice President Corporate Finance (October 2019 - November 2021) and VP Finance, International Markets (April 2014 - October 2019). Prior to joining Teva, Mr. Weiss served as Corporate Controller at RADCOM Ltd. from 2008 to 2012. From 2006 to 2008, he served as Corporate Controller at Oblicore Inc. Mr. Weiss holds an MA in law, an MBA and a Bachelor’s degree in Economics and Accounting from Bar Ilan University. Mr. Weiss is a Certified Public Accountant.

In connection with his promotion to Senior Vice President and Chief Accounting Officer, Mr. Weiss’s terms of employment were modified to increase his initial base salary to 840,000 New Israeli Shekels, with eligibility to be considered for an annual cash incentive with a target amount equal to 50% of his annual base salary and for equity-based awards under the Company’s equity compensation plan.

Mr. Weiss does not have any family relationships with any of the Company’s directors or executive officers and is not party to any transactions required to be disclosed under Item 404(a) of Regulation S-K.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Date: November 24, 2021     By:  

/s/ Eli Kalif

    Name:   Eli Kalif
    Title:   Executive Vice President, Chief Financial Officer

 

3

EX-101.SCH 2 teva-20211122.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 teva-20211122_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Address, Country Entity Address, Country Entity Tax Identification Number Entity Tax Identification Number Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 teva-20211122_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 d222550d8k_htm.xml IDEA: XBRL DOCUMENT 0000818686 2021-11-22 2021-11-22 TEVA PHARMACEUTICAL INDUSTRIES LTD IL 00-0000000 false 0000818686 8-K 2021-11-22 L3 001-16174 124 Dvora Hanevi’a Street Tel Aviv 6944020 972 3-914-8213 false false false false American Depositary Shares, each representing one Ordinary Share TEVA NYSE false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 22, 2021
Cover [Abstract]  
Entity Registrant Name TEVA PHARMACEUTICAL INDUSTRIES LTD
Entity Address, Country IL
Entity Tax Identification Number 00-0000000
Amendment Flag false
Entity Central Index Key 0000818686
Document Type 8-K
Document Period End Date Nov. 22, 2021
Entity Incorporation State Country Code L3
Entity File Number 001-16174
Entity Address, Address Line One 124 Dvora Hanevi’a Street
Entity Address, City or Town Tel Aviv
Entity Address, Postal Zip Code 6944020
City Area Code 972
Local Phone Number 3-914-8213
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title American Depositary Shares, each representing one Ordinary Share
Trading Symbol TEVA
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d222550d8k.htm teva-20211122.xsd teva-20211122_lab.xml teva-20211122_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d222550d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d222550d8k.htm" ] }, "labelLink": { "local": [ "teva-20211122_lab.xml" ] }, "presentationLink": { "local": [ "teva-20211122_pre.xml" ] }, "schema": { "local": [ "teva-20211122.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 5 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "teva", "nsuri": "http://www.tevapharm.com/20211122", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d222550d8k.htm", "contextRef": "duration_2021-11-22_to_2021-11-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d222550d8k.htm", "contextRef": "duration_2021-11-22_to_2021-11-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tevapharm.com//20211122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001193125-21-339389-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-339389-xbrl.zip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end